within Pharmacolibrary.Drugs.ATC.S;

model S01FA56
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 15 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tropicamide, in combination with other agents, is used primarily as a mydriatic and cycloplegic agent in ophthalmology. It is indicated for procedures requiring pupil dilation and paralysis of accommodation, such as eye examinations and preoperative preparations. Tropicamide combination products are approved and widely used today in clinical practice.</p><h4>Pharmacokinetics</h4><p>No published population or compartmental pharmacokinetic parameters were identified for tropicamide combinations (ATC S01FA56) in humans. The following pharmacokinetic parameters were estimated based on data from single-agent tropicamide ophthalmic administration in healthy adults.</p><h4>References</h4><ol><li><p>Doughty, MJ, &amp; Lyle, WM (1992). A review of the clinical pharmacokinetics of pilocarpine, moxisylyte (thymoxamine), and dapiprazole in the reversal of diagnostic pupillary dilation. <i>Optometry and vision science : official publication of the American Academy of Optometry</i> 69(5) 358–368. DOI:<a href=&quot;https://doi.org/10.1097/00006324-199205000-00005&quot;>10.1097/00006324-199205000-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1350669/&quot;>https://pubmed.ncbi.nlm.nih.gov/1350669</a></p></li><li><p>Seliniotaki, AK, et al., &amp; Mataftsi, A (2022). Efficacy and safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening (MyMiROPS): study protocol for a non-inferiority crossover randomized controlled trial. <i>Trials</i> 23(1) 322–None. DOI:<a href=&quot;https://doi.org/10.1186/s13063-022-06243-7&quot;>10.1186/s13063-022-06243-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35428316/&quot;>https://pubmed.ncbi.nlm.nih.gov/35428316</a></p></li><li><p>Pescina, S, et al., &amp; Nicoli, S (2017). Mydriatics release from solid and semi-solid ophthalmic formulations using different in vitro methods. <i>Drug development and industrial pharmacy</i> 43(9) 1472–1479. DOI:<a href=&quot;https://doi.org/10.1080/03639045.2017.1318910&quot;>10.1080/03639045.2017.1318910</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28426341/&quot;>https://pubmed.ncbi.nlm.nih.gov/28426341</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01FA56;
